Defense contractor Leidos (NYSE:LDOS) announced better-than-expected revenue in Q2 CY2026, with sales up 7.2% year on year to $4.56 billion. The company expects the full year’s revenue to be around $18.3 billion, close to analysts’ estimates. Its non-GAAP profit of $3.26 per share was 12.1% above analysts’ consensus estimates.
Is now the time to buy LDOS? Find out in our full research report (it’s free for active Edge members).
Leidos (LDOS) Q2 CY2026 Highlights:
- Revenue: $4.56 billion vs analyst estimates of $4.44 billion (7.2% year-on-year growth, 2.6% beat)
- Adjusted EPS: $3.26 vs analyst estimates of $2.91 (12.1% beat)
- Adjusted EBITDA: $631 million vs analyst estimates of $594.6 million (13.8% margin, 6.1% beat)
- The company slightly lifted its revenue guidance for the full year to $18.3 billion at the midpoint from $18.2 billion
- Management slightly raised its full-year Adjusted EPS guidance to $12.35 at the midpoint
- Operating Margin: 11.3%, down from 13.4% in the same quarter last year
- Backlog: $48.71 billion at quarter end, up 5.4% year on year
- Market Capitalization: $16.39 billion
StockStory’s Take
Leidos’ second quarter was marked by strong revenue momentum and a positive market reaction, reflecting solid execution in its core defense and homeland segments. Management highlighted that increased demand for defense technology programs and robust bookings, particularly in the Defense segment, were key contributors to growth. CEO Thomas Bell emphasized, “Defense posted a 2.2 book-to-bill ratio in the second quarter,” underscoring accelerated customer procurement activity and Leidos’ unique position in several emerging defense tech programs. The Health segment faced administrative changes, but management noted proactive cost management and ongoing efficiencies.
Looking forward, Leidos’ updated guidance is anchored by ongoing expansion across its defense technology, energy, and cyber growth pillars. Management pointed to accelerating momentum in defense awards, continued strength in homeland security projects, and efforts to diversify beyond legacy health contracts. CFO Chris Cage explained, “We expect the rest of Leidos to grow approximately 7% in revenues and 19% in adjusted EBITDA in 2026,” as new program ramp-ups and the company’s low capital intensity support sustained cash generation. Leidos is also navigating changes in customer contracting approaches, particularly with in-sourcing trends, but remains confident in its differentiated capabilities and scale.
Key Insights from Management’s Remarks
Management attributed the quarter’s outperformance to robust defense segment bookings, efficiency gains in Health, and a balanced capital deployment strategy, while also navigating evolving government procurement trends and shifting customer requirements.
- Defense segment momentum: Leidos saw significant acceleration in defense bookings, highlighted by a 2.2 book-to-bill ratio and increased activity in munitions, space, and maritime programs. Management believes this positions the company well for future production awards, with a $12 billion pipeline in defense opportunities over the next 12 months.
- Health segment adaptation: The Health segment faced the suspension of incentive payments for its medical disability exam business, driven by administrative reviews at the VA. Leidos proactively worked with the VA to apply cost-saving technologies and expects health margins to remain stable, with new contract structures under negotiation for next year.
- Low capital intensity focus: Leidos maintained a low capital intensity approach, allowing for higher free cash flow generation. The company’s enterprise transformation office is working to further optimize working capital, supporting ongoing investments in growth pillars without significantly increasing capital expenditures.
- Homeland and energy growth: The Homeland segment benefited from strong demand in commercial energy infrastructure and air traffic management. Management cited robust international activity and minimal exposure to U.S. government shutdown risks due to the segment’s global footprint.
- Capital deployment flexibility: Leidos completed its previous share repurchase authorization and introduced a new program, while also signaling a cautious stance on major acquisitions given current market valuations. The company remains committed to balanced capital allocation, prioritizing organic growth, targeted M&A, and shareholder returns as conditions allow.
Drivers of Future Performance
Leidos expects future growth to be shaped by rising defense tech demand, ongoing diversification efforts, and prudent cost management, while monitoring potential headwinds in health contracting and government funding cycles.
- Defense tech ramp-up: Management anticipates continued acceleration in defense revenue as new hardware and software integration programs enter production. CEO Thomas Bell noted that munitions, autonomy, and space sensing payloads are now key engines driving the Defense segment’s outlook, with double-digit revenue and margin growth expected over the medium term.
- Health segment uncertainty: The health business faces some risk due to changing incentive models and pending contract recompetes with the VA. While Leidos is working to resecure its position, management cautioned that near-term health margins will be shaped by evolving contract terms and administrative decisions, though they expect baseline volumes and efficiencies to provide stability.
- Government procurement dynamics: Shifts toward fixed-price contracts and increased in-sourcing by government agencies may affect revenue mix and margin structure. However, Leidos’ investments in secure cloud, AI, and full-spectrum cyber capabilities are designed to address these trends and support continued bookings growth, particularly in intelligence and homeland segments.
Catalysts in Upcoming Quarters
In the coming quarters, our team will monitor (1) the pace of major defense award conversions and production ramp-ups, (2) the outcome and structure of the pending VA health contract recompete, and (3) the impact of fixed-price contracting and in-sourcing across key government customers. Execution in emerging technology partnerships and continued cash flow discipline will also be central to tracking Leidos’ progress.
Leidos currently trades at $130.48, up from $118.72 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).
Now Could Be The Perfect Time To Invest In These Stocks
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
